GlassScriptPhysician profile
Wendy L Weinstein
NPI 1679523484
$387,693.19
in general payments reported to CMS, 2019-2025
33 companies · $57K in 2025
The $57K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $18K · 2021: $27K · 2022: $36K · 2023: $111K · 2024: $91K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $223K · Travel and Lodging: $21K · Food and Beverage: $14K · Consulting Fee: $1,472 · Education: $6.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $222,637.40 |
| Travel and Lodging | $21,186.86 |
| Food and Beverage | $13,655.94 |
| Consulting Fee | $1,472.00 |
| Education | $6.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $126,350.33 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $118,490.91 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $60,798.45 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $23,691.36 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $9,568.40 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $9,465.48 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $8,601.31 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $8,092.08 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $7,953.44 | 2019-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $7,924.38 | 2022-2024 | Quviviq |
| Alkermes, INC. | $1,671.09 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $1,243.43 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $1,159.56 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $850.74 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $303.31 | 2022-2025 | Auvelity, Sunosi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $283.53 | 2022-2024 | Azstarys |
| Eisai INC. | $244.86 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $163.99 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $131.01 | 2025 | Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $128.44 | 2022-2023 | |
| Neos Therapeutics, LP | $92.90 | 2019-2025 | Exxua |
| Indivior INC. | $79.31 | 2019 | |
| Avanir Pharmaceuticals, INC. | $66.77 | 2021-2022 | |
| Neuronetics, INC. | $56.15 | 2019 | |
| Biogen, INC. | $52.99 | 2024-2025 | Zurzuvae |
| Bausch Health US, LLC | $41.38 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $36.69 | 2019 | |
| Arbor Pharmaceuticals, INC. | $35.74 | 2019 | |
| Shire North American Group INC | $33.61 | 2019 | |
| Alfasigma USA, INC. | $30.83 | 2020-2021 | |
| Luye Pharma (USA) LTD. | $20.47 | 2025 | Erzofri Extended-Release |
| Sage Therapeutics, LLC | $15.75 | 2023 | |
| Noven Therapeutics, LLC | $14.50 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.